First of a new breed of anticancer antibodies approved in Japan


The first in a new class of immune-oncology drugs has been approved for use in Japan. Ono pharmaceuticals’ Opdivo (nivolumab) has been approved for treating melanomas where surgery is impossible.

Nivolumab is part of a new wave of cancer therapies that encourage our immune systems to fight cancers or enhance their performance. It targets programmed cell death (PD1) receptors that are expressed on tumour cell surfaces to ward off detection by the immune system.

Ono developed the monoclonal antibody in conjunction with US biotech Medarex, which was acquired by Bristol-Myers Squib (BMS) in 2009. BMS is developing the drug outside of Japan, Korea and Taiwan.


Related Content

First biosimilar antibody drugs approved in Europe

11 September 2013 Business

news image

European commission gives final approval to generic infliximab copies

Pharma queues up for checkpoint inhibitor collaborations

3 July 2015 Business

news image

Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits

Most Read

US government science institute's one time police chief linked to campus meth lab

31 July 2015 News and Analysis

news image

Explosion injuring a member of the National Institute of Standards and Technology's security force uncovered methamphetamine ...

(–)-Jiadifenolide

27 July 2015 Organic Matter

news image

BRSM wonders what makes a route so good it becomes the last total synthesis of a complex target

Most Commented

Scientist imprisoned over fraudulent HIV vaccine research

6 July 2015 News and Analysis

news image

Former Iowa State University researcher gets four-and-a-half years in prison for faking vaccine research funded by the NIH

Single polymer pill could deliver entire drug course in one go

27 July 2015 Research

news image

Flexible elastomer ring springs open to stay in stomach and could slowly release drugs over days